
Founder-friendly capital for category-defining medtech companies.
We partner with medtech founders advancing cardiology, neurotech and adjacent technologies through financing, commercialization and strategic growth.
What Makes Us Different
Built by operators.
Aligned with founders.
Focused on execution.
Metis is an alternative to traditional venture capital, designed from the operator’s seat for founders building the next generation of cardiology and neurotech companies.
Founder Partnership
Aligned capital. Shared incentives. Founder control respected.
Strategic Foresight
Pattern recognition across financing, regulatory, and commercial milestones.
Operational Execution
Hands-on guidance from company formation through scale.
Enduring Value
Build category-defining medtech companies with durable long-term value.
Where We Focus
Concentrated expertise where operator pattern recognition matters most.
Cardiology
Structural heart, electrophysiology and interventional cardiovascular platforms.
Neurotechnology
Neurovascular, neuromodulation and neurosurgical innovation.
Adjacent Medtech
High-impact medical device categories with operator-driven growth potential.
Portfolio
Current Investments & Advisory Activity
Supporting founders with friendly capital, strategic guidance and operational support from the pre-clinical R&D phase through regulatory approval, scaling sales and strategic acquisition.
Proven Track Record
Experience behind category-defining medtech exits.
Four successful exits representing more than $1.25B in aggregate transaction value.

About
An alternative to traditional venture capital, built by an operator.
Metis MedTech was founded on a simple premise: founders building category-defining medical device companies deserve capital and guidance from someone who has done it themselves.
Our work spans financing strategy, regulatory navigation, commercialization and exit pattern recognition, informed by four successful medical device exits and decades of operator-level experience.
News
John Slump Launches Metis MedTech Following Atraverse Medical Acquisition by Johnson & Johnson
Repeat medtech founder and operator behind multiple nine-figure exits launches investment and strategic advisory platform to help founders build, fund and scale medical device companies.
CHICAGO — May 28, 2026 — John Slump, co-founder and former president and CEO of Atraverse Medical, announced the launch of Metis MedTech, an investment and strategic advisory platform for medical device founders. The launch follows the close of Johnson & Johnson’s (NYSE: JNJ) acquisition of Atraverse Medical on May 15, 2026, which strengthens its J&J MedTech cardiac electrophysiology portfolio.
Founder Inquiry
Building a category-defining medtech company?
Submit a founder inquiry. If there’s strategic fit, we’ll be in touch.


